Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

AB1870 Anti-Osteopontin Antibody

View Products on Sigmaaldrich.com
AB1870
100 µL  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Spec Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
H, M, RELISA, IHC, IH(P), WBRbSerumPolyclonal Antibody
Description
Catalogue NumberAB1870
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-Osteopontin Antibody
Alternate Names
  • Uropontin
  • Bone sialoprotein 1
  • SPP1/CALPHA1 fusion
  • Urinary stone protein
  • bone sialoprotein I
  • osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein
  • secreted phosphoprotein 1
  • secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
  • secreted phosphoprotein-1 (osteoponti,
  • bone sialoprotein)
Background InformationOsteopontin is a single-chain polypeptide with a molecular weight of approximately 35 kDa. It is a glycoprotein first identified in osteoblasts. It is biosynthesized by a variety of tissue types including preosteoblasts, osteoblasts, osteocytes, extraosseous cells in the inner ear, brain, kidney, deciduum, placenta, odontoblasts, some bone marrow cells, hypertrophic chondrocytes, macrophages, smooth muscle, and endothelial cells. Osteopontin is overexpressed in a variety of cancers, including lung cancer, breast cancer, colorectal cancer, stomach cancer, ovarian cancer, melanoma and mesothelioma. It may contribute to kidney stone formation and both glomerulonephritis and tubulointerstitial nephritis and is also found in atheromatous plaques within arteries. Research has implicated osteopontin in excessive scar-forming and a gel has been developed to inhibit its effect.
References
Product Information
FormatSerum
HS Code3002 15 90
Control
  • POSITIVE CONTROL: Human urine (2-5 µg/mL normal concentration).
PresentationRabbit polyclonal antiserum in buffer containing no preservatives.
Quality LevelMQ100
Applications
ApplicationThis Anti-Osteopontin Antibody is validated for use in ELISA, IH, IH(P), WB for the detection of Osteopontin.
Key Applications
  • ELISA
  • Immunohistochemistry
  • Immunohistochemistry (Paraffin)
  • Western Blotting
Application NotesImmunohistochemistry:
A previous lot of this antibodu was used at a 1:1500 dilution on paraffin-embedded tissue sections.

ELISA:
A previous lot of this antibody was used at a 1:1000 dilution.

Optimal working dilutions must be determined by end user.
Biological Information
ImmunogenSynthetic peptide corresponding to amino acids 75-90 of human osteopontin (SwissProt Accession # P10451; PSKSNESHDHMDDM DD).
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostRabbit
SpecificityHuman osteopontin. Does not cross react with osteonectin or human bone sialoprotein II.
Species Reactivity
  • Human
  • Mouse
  • Rat
Species Reactivity NoteHuman and Mouse. Expected to cross-react with rat.
Antibody TypePolyclonal Antibody
Entrez Gene Number
Gene Symbol
  • SPP1
  • BNSP
  • MGC110940
  • Uropontin
  • Nephropontin
  • CIT:779436
  • osteopontin
  • SPP-1
  • BSPI
  • OPN
  • ETA-1
Purification MethodUnpurified
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P10451 # Acts as a cytokine involved in enhancing production of interferon-gamma and interleukin-12 and reducing production of interleukin-10 and is essential in the pathway that leads to type I immunity (By similarity).
SIZE: 314 amino acids; 35423 Da
SUBUNIT: Ligand for integrin alpha-V/beta-3.
SUBCELLULAR LOCATION: Secreted.
PTM: Extensively phosphorylated on clustered serine residues. & N- and O-glycosylated.
DISEASE:SwissProt: P10451 # This protein plays a principal role in urinary stone formation as the stone matrix.
SIMILARITY: SwissProt: P10451 ## Belongs to the osteopontin family.
Molecular Weight~35 kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceRoutinely evaluated by Western Blot on RAW 264.7 lysates.

Western Blot Analysis: 1:500 dilution of this lot detected osteopontin on 10 μg of RAW 264.7 lysates.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at -20°C in undiluted aliquots from date of receipt.

Handling Recommendations:
Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Packaging Information
Material Size100 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
AB1870 04053252476570

Documentation

Anti-Osteopontin Antibody SDS

Title

Safety Data Sheet (SDS) 

Anti-Osteopontin Antibody Certificates of Analysis

TitleLot Number
Anti-Osteopontin - 0702052391 0702052391
Anti-Osteopontin - 1997911 1997911
Anti-Osteopontin - 2172681 2172681
Anti-Osteopontin - 3046809 3046809
Anti-Osteopontin - 3427283 3427283
Anti-Osteopontin - 3810238 3810238
Anti-Osteopontin - 4059346 4059346
Anti-Osteopontin - 4105204 4105204
Anti-Osteopontin - JC1641493 JC1641493
Anti-Osteopontin - JC1673163 JC1673163

References

Reference overviewApplicationPub Med ID
Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection.
Matsue, Y; Tsutsumi, M; Hayashi, N; Saito, T; Tsuchishima, M; Toshikuni, N; Arisawa, T; George, J
PloS one  10  e0118744  2015

Show Abstract
25760884 25760884
Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model
Carla Patrícia Carlos 1 , Nathália Martins Sonehara 2 , Sonia Maria Oliani 2 , Emmanuel A Burdmann
Plos One  9(7)  e103660  2014

Show Abstract
Immunohistochemistry25072153 25072153
Expression and localisation of osteopontin and prominin-1 (CD133) in patients with endometriosis.
D'Amico, F; Skarmoutsou, E; Quaderno, G; Malaponte, G; La Corte, C; Scibilia, G; D'Agate, G; Scollo, P; Fraggetta, F; Spandidos, DA; Mazzarino, MC
International journal of molecular medicine  31  1011-6  2013

Show Abstract
23545719 23545719
Sequential application of steady and pulsatile medium perfusion enhanced the formation of engineered bone.
Correia, C; Bhumiratana, S; Sousa, RA; Reis, RL; Vunjak-Novakovic, G
Tissue engineering. Part A  19  1244-54  2013

Show Abstract
Immunohistochemistry23259605 23259605
MG63 osteoblast-like cells exhibit different behavior when grown on electrospun collagen matrix versus electrospun gelatin matrix.
Tsai, SW; Liou, HM; Lin, CJ; Kuo, KL; Hung, YS; Weng, RC; Hsu, FY
PloS one  7  e31200  2012

Show Abstract
Western Blotting22319618 22319618
Development of silk-based scaffolds for tissue engineering of bone from human adipose-derived stem cells.
Correia, C; Bhumiratana, S; Yan, LP; Oliveira, AL; Gimble, JM; Rockwood, D; Kaplan, DL; Sousa, RA; Reis, RL; Vunjak-Novakovic, G
Acta biomaterialia  8  2483-92  2012

Show Abstract
Immunohistochemistry22421311 22421311
ATF5, a possible regulator of osteogenic differentiation in human adipose-derived stem cells.
David Tai Leong,Mohan Chothirakottu Abraham,Anurag Gupta,Thiam-Chye Lim,Fook Tim Chew,Dietmar Werner Hutmacher
Journal of cellular biochemistry  113  2012

Show Abstract
22442021 22442021
Optimizing the medium perfusion rate in bone tissue engineering bioreactors.
Grayson, WL; Marolt, D; Bhumiratana, S; Fröhlich, M; Guo, XE; Vunjak-Novakovic, G
Biotechnology and bioengineering  108  1159-70  2011

Show Abstract
Immunohistochemistry21449028 21449028
Elevated Osteopontin Expression and Proliferative/Apoptotic Ratio in the Colorectal Adenoma-Dysplasia-Carcinoma Sequence.
Valcz G, Sipos F, Krenács T, Molnár J, Patai AV, Leiszter K, Tóth K, Solymosi N, Galamb O, Molnár B, Tulassay Z
Pathol Oncol Res  2010

Show Abstract
20349162 20349162
Reduced expression of biomarkers associated with the implantation window in women with endometriosis.
Qingxiang Wei, J Benjamin St Clair, Teresa Fu, Pamela Stratton, Lynnette K Nieman, Qingxiang Wei, J Benjamin St Clair, Teresa Fu, Pamela Stratton, Lynnette K Nieman, Qingxiang Wei, J Benjamin St Clair, Teresa Fu, Pamela Stratton, Lynnette K Nieman
Fertility and sterility  91  1686-91  2009

Show Abstract Full Text Article
18672236 18672236